switching from tirzepatide to semaglutide for maintenance between weight-loss medications Switching from semaglutide to tirzepatide

Tirzepatide produced greater average weight and waist reduction, while gastrointestinal adverse events were most common with both medications and were generally mild to moderate

Yet current research on the medications is just scratching the surface, says Marty Lerner, PhD, founder of Milestones, an eating disorder recovery program based in Florida

Today, GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro are arguably the closest we have come to a magic bullet. The metabolic results are undeniable, but as prescriptions skyrocket, so does a unique aesthetic concern dominating social media: Ozempic face aging

J.LiH.DingH.LvQ.HouS